多項目クラミジア・トラコマティスおよび淋菌NAAT市場（金額、数量、ASP）：セグメント別規模、シェア、動向およびSWOT分析、法規制および償還動向、手技、2033年までの予測

クラミジアは一般的な性感染症であり、クラミジア・トラコマティスという細菌によって引き起こされます。女性の場合、クラミジア・トラコマティス感染症は多くの場合無症状ですが、放置すると骨盤内炎症性疾患（PID）を引き起こし、さらに不妊症、子宮外妊娠、慢性骨盤痛などの合併症を引き起こす可能性があります。淋病は世界的に最も一般的な性感染症（STD）の一つで、淋菌によって引き起こされます。淋菌感染症は若年成人に多くみられます。淋菌に感染するリスクが高いその他のグループには、複数の性的パートナーがいる人、他のSTDに罹患している人、男性と性交渉を持つ男性（MSM）、セックスワーカーなどが含まれます。

当レポートは、世界の多項目クラミジア・トラコマティスおよび淋菌NAAT市場について詳細に考察し、市場における競合情勢、SWOT分析、2033年までの市場予測、COVID-19の影響、地域、国別の動向などを提供しています。

目次

現在上市されている多項目クラミジア・トラコマティスおよび淋菌NAATと競合情勢

• 主要な業界動向の洞察
• 多項目クラミジア・トラコマティスおよび淋菌NAATのセグメント別総市場収益と2015年～2033年の市場展望
• 台数、平均販売価格、市場価値に関する詳細データ

世界、地域、国別の洞察

• 多項目クラミジア・トラコマティスおよび淋菌NAAT市場のSWOT分析
• 多項目クラミジア・トラコマティスおよび淋菌NAAT市場に関する競合力学の洞察と動向
• 国別の医療制度の概要
• 国別の償還政策
• 国別の医療技術に関する規制の状況

Abstract

Multi Parameter Chlamydia Trachomatis and Neisseria Gonorrhoeae NAATs Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Multi parameter Chlamydia Trachomatis and Neisseria Gonorrhoeae NAATs Tests market for the year 2020 and beyond. Chlamydia is a common sexually transmissible disease, caused by the bacteria Chlamydia Trachomatis. In women, Chlamydia Trachomatis infections are often asymptomatic, however, if left untreated they can cause pelvic inflammatory disease (PID), which in turn can lead to additional complications such as infertility, ectopic pregnancy, and chronic pelvic pain. Gonorrhoea is one of the most common sexually transmitted disease (STD) worldwide, caused by the bacteria Neisseria gonorrhoea. N. gonorrhoea infections are more common in young adults. Other groups at higher risk of contracting gonorrhoea include individuals with multiple sexual partners, individuals with another STD, men who have sex with men (MSM), and sex workers.

This model includes Multi-parameter Chlamydia Trachomatis and Neisseria Gonorrhoeae NAATs.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Multi parameter Chlamydia Trachomatis and Neisseria Gonorrhoeae NAATs and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total Multi parameter Chlamydia Trachomatis and Neisseria Gonorrhoeae NAATs market revenue by segment and market outlooks from 2015- 2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Multi parameter Chlamydia Trachomatis and Neisseria Gonorrhoeae NAATs market.
• Competitive dynamics insights and trends provided for Multi parameter Chlamydia Trachomatis and Neisseria Gonorrhoeae NAATs market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories, Becton Dickinson and Co, Danaher Corp, F. Hoffmann-La Roche Ltd, Hologic Inc, and others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for:

• CMO executives who must have deep understanding of the Multi parameter Chlamydia Trachomatis and Neisseria Gonorrhoeae NAATs market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to:

• Understand the impact of COVID-19 on Multi parameter Chlamydia Trachomatis and Neisseria Gonorrhoeae NAATs market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Multi parameter Chlamydia Trachomatis and Neisseria Gonorrhoeae NAATs market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Multi parameter Chlamydia Trachomatis and Neisseria Gonorrhoeae NAATs market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific Multi parameter Chlamydia Trachomatis and Neisseria Gonorrhoeae NAATs market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.